The ART1 Knockout SK-OV-3 Polyclonal Cells product comprises a CRISPR/Cas9-edited polyclonal population of SK-OV-3 human ovarian adenocarcinoma cells harboring a targeted disruption of the ART1 gene. This polyclonal knockout pool is engineered to ablate arginine-specific mono-ADP-ribosyltransferase 1 (ART1) expression, generating a versatile loss-of-function model for investigating ART1-mediated post-translational modifications in cancer biology. The use of a polyclonal knockout format ensures a heterogeneous population with diverse genetic backgrounds, enabling robust phenotypic studies without the biases associated with single-cell clones.
The parental SK-OV-3 cell line is a widely employed epithelial adenocarcinoma model isolated from the ascitic fluid of a patient with ovarian cancer. These cells exhibit epithelial morphology and retain key oncogenic signaling pathways characteristic of high-grade serous ovarian carcinoma. As an established in vitro system, SK-OV-3 is extensively utilized for mechanistic studies of tumor progression, metastasis, and drug response, providing a clinically relevant background for ART1 functional analyses.
ART1 encodes a glycosylphosphatidylinositol (GPI)-anchored ectoenzyme that catalyzes the transfer of ADP-ribose from NAD+ to arginine residues on target proteins, including P2RX7, ITGA7, and FGF2. This mono-ADP-ribosylation modulates receptor and integrin function, influencing downstream signaling. ART1 expression is transcriptionally regulated by STAT1 and NF-??B in response to interferon-gamma (IFNG), tumor necrosis factor (TNF), and lipopolysaccharide (LPS). ART1 modification of P2RX7 regulates calcium influx and purinergic signaling, while ADP-ribosylation of ITGA7 affects integrin-mediated adhesion. Additionally, ART1 can modify FGF2, impacting FGF receptor signaling. Through these interactions, ART1 integrates extracellular cues with cellular responses, positioning it at the nexus of inflammation, adhesion, and growth factor pathways.
In SK-OV-3 ovarian cancer cells, ART1 knockout is expected to disrupt ADP-ribosylation of surface proteins, thereby altering key tumorigenic processes. Abrogation of ART1 activity may impair P2RX7-dependent calcium signaling and downstream NF-??B activation, potentially reducing pro-inflammatory and pro-survival signals. Loss of ART1-mediated ITGA7 modification could weaken integrin-mediated adhesion to extracellular matrix components, affecting cell migration and invasion. Furthermore, reduced ADP-ribosylation of FGF2 may blunt FGF receptor signaling, influencing proliferation and angiogenesis. Collectively, this knockout model provides a platform to dissect ART1??s contributions to ovarian cancer progression and the tumor microenvironment.
This polyclonal knockout cell pool is suited for diverse research applications, including elucidation of ART1-mediated ADP-ribosylation mechanisms in ovarian cancer, functional interrogation of the P2RX7/ART1 signaling axis, and screening of small-molecule ADP-ribosyltransferase inhibitors. Researchers can confirm ART1 disruption via western blotting or immunofluorescence, assess ADP-ribosylation activity using biotin-NAD+ labeling, measure P2RX7 calcium influx, evaluate cell adhesion to integrin substrates, conduct proliferation (MTS) and Transwell migration/invasion assays, and perform transcriptomic profiling by RNA-seq. These tools enable comprehensive investigation of ART1-dependent phenotypes and therapeutic vulnerabilities. For further information, please contact Ascent Research.
